5‐HT1A Receptor Agonist Flesinoxan Enhances Fos Immunoreactivity in Rat Central Amygdala, Bed Nucleus of the Stria Terminalis and Hypothalamus
- 1 November 1996
- journal article
- Published by Wiley in European Journal of Neuroscience
- Vol. 8 (11) , 2340-2347
- https://doi.org/10.1111/j.1460-9568.1996.tb01197.x
Abstract
5‐Hydroxytryptamine‐1A (5‐HT1A) receptor agonists, including flesinoxan, reduce anxiety and activate the hypothalamus‐pituitary‐adrenal (HPA) axis under basal conditions. In order to investigate the underlying neural mechanisms we investigated immunoreactivity for the immediate early gene protein product Fos (Fos‐ir) in rat brains 1 h after flesinoxan treatment (0.0, 0.3 or 3.0 mg/kg p.0.). Typically, 5‐HT1A receptor‐containing brain areas, such as the dorsal raphe nuclei, hippocampus, septum, diagonal band and the cortical and basomedial amygdala, do not show Fos‐ir. Apparently, binding of flesinoxan at the 5‐HT1A receptor does not directly lead to activation of c‐fos in the cell, probably due to its negative coupling to adenylate cyclase. However, in typically non‐5HTlA receptor‐containing brain areas Fos‐ir is increased due to flesinoxan treatment, as in the paraventricular nucleus of the hypothalamus (PVN), the dorsolateral part of the bed nucleus of the stria terminalis (BNSTd1) and the central amygdala (CeA). Flesinoxan‐treated rats also exhibited higher plasma corticosterone levels than vehicle‐treated animals, which suggests the involvement of corticotropin‐releasing hormone (CRH) or vasopressin in the hypothalamus. After double immunolabelling (Fos/CRH or Fos/vasopressin), every CRH neuron detected in the PVN also contained Fos. Moreover, a significant correlation existed between the number of Fos‐ir neurons in the PVN and the plasma corticosterone level. Hardly any Fos/ vasopressin double labelling was visible in the PVN. Accordingly, flesinoxan exerts its activating effects on the HPA axis via CRH neurons in the PVN. These effects are transsynaptically mediated by other brain areas, such as the CeA and BNSTdl, which also show increased Fos‐ir.Keywords
This publication has 42 references indexed in Scilit:
- Differential effect of amygdaloid lesions on CRF-41, ACTH and corticosterone responses following neural stimuliBrain Research, 1994
- Serotonin 5‐HT1A Receptor Activation Increases Cyclic AMP Formation in the Rat Hippocampus In VivoJournal of Neurochemistry, 1994
- Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperatureHuman Psychopharmacology: Clinical and Experimental, 1993
- A review of clinical efficacy of 5-HT 1A agonists in anxiety and depressionJournal of Psychopharmacology, 1993
- Vasopressinergic Control of Pituitary Adrenocorticotropin Secretion Comes of AgeFrontiers in Neuroendocrinology, 1993
- Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain — a combined in situ hybridisation/in vitro receptor autoradiographic studyBrain Research, 1991
- The preoptic area and bed nucleus of the stria terminalis are involved in the effects of the amygdala on adrenocortical secretionNeuroscience, 1990
- Direct Projections from the Central Amygdaloid Nucleus to the Hypothalamic Paraventricular Nucleus: Possible Role in Stress-Induced Adrenocorticotropin ReleaseNeuroendocrinology, 1989
- Mechanisms of effects of d-Fenfluramine on brain serotonin metabolism in rats: Uptake inhibition versus releasePharmacology Biochemistry and Behavior, 1988
- Stress Hormones: Their Interaction and RegulationScience, 1984